Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
O'Hallahan, J; Lennon, D; Oster, P; Lane, R; Reid, S; MULHOLLAND, K; Stewart, J; Penney, L; Percival, T; Martin, D;
2005
Vaccine, (2005).23 17-18 10.1016/j.vaccine.2005.01.061.
Immunisation at the crossroads: 9th National Immunisation/1st Asia-Pacific Vaccine Preventable Diseases Conference.
McIntyre, PB; Kelly, HA; MULHOLLAND, EK;
2005
The Medical journal of Australia, (2005).182 1
Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
Ameratunga, S; Macmillan, A; Stewart, J; Scott, D; MULHOLLAND, K; Crengle, S; Meningococcal Management Team,;
2005
Vaccine, (2005).23 17-18 10.1016/j.vaccine.2005.01.048.
Practical aspects of phase 3 vaccine trials in developing countries.
GREENWOOD, B;
2005
The Grand Challenge for the Future , Birkhauser Verlag (Basel) (2005).
An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
MANGTANI, P; Roberts, JA; Hall, AJ; Cutts, FT;
2005
International journal of epidemiology, (2005).34 3 10.1093/ije/dyh341.
IgG antibodies to merozoite surface antigens are associated with recovery from chloroquine (CQ)-resistant P. falciparum in Gambian children [MIM-CS-62139].
Pinder, M; SUTHERLAND, CJ; Sisay-Joof, F; Ismaili, J; McCall, MB B; Ord, R; Hallett, R; Holder, AA; Milligan, P;
2005
ACTA TROPICA, (2005).95,
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.
Cutts, FT; ZAMAN, SM A; Enwere, G; Jaffar, S; Levine, OS; Okoko, JB; Oluwalana, C; Vaughan, A; Obaro, SK; Leach, A; McAdam, KP; Biney, E; Saaka, M; Onwuchekwa, U; Yallop, F; Pierce, NF; GREENWOOD, BM; Adegbola, RA; Gambian Pneumococcal Vaccine Trial Group,;
2005
Lancet, (2005).365 9465 10.1016/S0140-6736(05)71876-6.
A randomised controlled trial of the effects of albendazole in pregnancy on maternal responses to mycobacterial antigens and infant responses to Bacille Calmette-Guérin (BCG) immunisation [ISRCTN32849447].
ELLIOTT, AM; Namujju, PB; MAWA, PA; Quigley, MA; Nampijja, M; Nkurunziza, PM; Belisle, JT; Muwanga, M; WHITWORTH, JA G; Mother and Baby study team,;
2005
BMC infectious diseases, (2005).5 1 10.1186/1471-2334-5-115.
Malaria vaccine: 3 or 6 months' protection?.
SMITH, PG; MILLIGAN, PJ;
2005
Lancet, (2005).365 9458 10.1016/S0140-6736(05)17860-X.
Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis.
SOLOMON, AW; MABEY, DC W;
2005
Vaccine, (2005).23 46-47 10.1016/j.vaccine.2005.05.042.